BD Completes GeneOhm buy
This article was originally published in The Gray Sheet
Executive Summary
BD will launch a global initiative to reduce healthcare-associated infections after completing its acquisition of molecular diagnostic firm GeneOhm Sciences (1"The Gray Sheet" Jan. 16, 2006, p. 5). BD announced Jan. 10 that it would pay $230 mil., plus up to $25 mil. in milestone payments, to acquire the firm. Assays currently available from GeneOhm include the IDI-Strep B assay for detecting Group B Strep, and IDI-MRSA for detecting methicillin-resistant Staphylococcus aureus. BD has speculated that the market could be worth more than $500 mil...
You may also be interested in...
BD Targets Hospital-Associated Infections With $230 Mil. Acquisition
BD's acquisition of molecular diagnostic firm GeneOhm Sciences enters the medical technology company into the purportedly $500 mil.-plus healthcare-associated infections market
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.